{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:27:44Z","timestamp":1781702864117,"version":"3.54.5"},"reference-count":175,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM075061"],"award-info":[{"award-number":["GM075061"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK079307"],"award-info":[{"award-number":["DK079307"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL127930"],"award-info":[{"award-number":["HL127930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bbalip.2018.03.010","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T07:54:47Z","timestamp":1523001287000},"page":"762-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?"],"prefix":"10.1016","volume":"1863","author":[{"given":"Lynley M.","family":"Doonan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2018.03.010_bb0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0010","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0015","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/STR.0b013e31829734f2","article-title":"Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association","volume":"44","author":"Ovbiagele","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.amjmed.2014.03.017","article-title":"Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008","volume":"127","author":"Fang","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The response-to-retention hypothesis of early atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1258\/acb.2011.011111","article-title":"Apolipoproteins: metabolic role and clinical biochemistry applications","volume":"48","author":"Dominiczak","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0040","series-title":"Plasma Lipoproteins","article-title":"Plasma lipoproteins","volume":"vol. 2014","author":"Christie","year":"2014"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0045","series-title":"Clinical Methods: The History, Physical, and Laboratory Examinations","article-title":"Cholesterol, triglycerides, and associated lipoproteins","author":"Cox","year":"1990"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nrd2353","article-title":"Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery","volume":"7","author":"Wasan","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/wsbm.82","article-title":"APOBEC-1-mediated RNA editing","volume":"2","author":"Blanc","year":"2010","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tibs.2016.05.001","article-title":"The APOBEC protein family: united by structure, divergent in function","volume":"41","author":"Salter","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0065","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fimmu.2017.00351","article-title":"A novel regulator of activation-induced cytidine deaminase\/APOBECs in immunity and cancer: Schrodinger's CATalytic pocket","volume":"8","author":"King","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0070","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/nar\/22.10.1874","article-title":"Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein","volume":"22","author":"Hadjiagapiou","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0075","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1016\/S0021-9258(17)37551-8","article-title":"Complementation of apolipoprotein B mRNA editing by human liver accompanied by secretion of apolipoprotein B48","volume":"269","author":"Giannoni","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0080","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cca.2016.02.004","article-title":"Chylomicrons: advances in biology, pathology, laboratory testing, and therapeutics","volume":"455","author":"Julve","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0085","doi-asserted-by":"crossref","first-page":"G659","DOI":"10.1152\/ajpgi.00228.2015","article-title":"Control of chylomicron export from the intestine","volume":"310","author":"Mansbach","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/1755-5922.12105","article-title":"Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance","volume":"33","author":"Kolovou","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0100","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1016\/S0021-9258(19)38742-3","article-title":"Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex","volume":"265","author":"Wetterau","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.bbalip.2018.03.010_bb0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/bj3150533","article-title":"The role of protein disulphide isomerase in the microsomal triacylglycerol transfer protein does not reside in its isomerase activity","volume":"315","author":"Lamberg","year":"1996","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-2275(20)37627-6","article-title":"Role of intramolecular disulfide bond formation in the assembly and secretion of apolipoprotein B-100-containing lipoproteins","volume":"37","author":"Shelness","year":"1996","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1074\/jbc.M007944200","article-title":"Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome","volume":"276","author":"Pariyarath","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0120","doi-asserted-by":"crossref","first-page":"31466","DOI":"10.1074\/jbc.M100390200","article-title":"Binding of microsomal triglyceride transfer protein to lipids results in increased affinity for apolipoprotein B: evidence for stable microsomal MTP-lipid complexes","volume":"276","author":"Bakillah","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/ATVBAHA.111.241471","article-title":"Intracellular trafficking and secretion of VLDL","volume":"32","author":"Tiwari","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0130","doi-asserted-by":"crossref","first-page":"48051","DOI":"10.1074\/jbc.M306898200","article-title":"Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER","volume":"278","author":"Gusarova","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/ATVBAHA.113.302728","article-title":"A regulator of secretory vesicle size, Kelch-like protein 12, facilitates the secretion of apolipoprotein B100 and very-low-density lipoproteins\u2014brief report","volume":"34","author":"Butkinaree","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1083\/jcb.201603072","article-title":"TANGO1 and Mia2\/cTAGE5 (TALI) cooperate to export bulky pre-chylomicrons\/VLDLs from the endoplasmic reticulum","volume":"213","author":"Santos","year":"2016","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature10822","article-title":"Ubiquitin-dependent regulation of COPII coat size and function","volume":"482","author":"Jin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0150","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins","volume":"291","author":"Smagris","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0155","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbalip.2016.03.009","article-title":"Liver-specific expression of carboxylesterase 1g\/esterase-x reduces hepatic steatosis, counteracts dyslipidemia and improves insulin signaling","volume":"1861","author":"Bahitham","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049515","article-title":"Carboxylesterase1\/esterase-x regulates chylomicron production in mice","volume":"7","author":"Quiroga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0165","doi-asserted-by":"crossref","first-page":"19453","DOI":"10.1074\/jbc.M700475200","article-title":"Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E","volume":"282","author":"Gusarova","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0170","doi-asserted-by":"crossref","first-page":"17377","DOI":"10.1074\/jbc.R100068200","article-title":"Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins","volume":"277","author":"Fisher","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"Suppl","key":"10.1016\/j.bbalip.2018.03.010_bb0175","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1194\/jlr.R800090-JLR200","article-title":"The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism","volume":"50","author":"Ginsberg","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0180","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/ATVBAHA.112.251116","article-title":"Apolipoprotein B secretory regulation by degradation","volume":"32","author":"Olofsson","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MOL.0b013e32835aebe7","article-title":"Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion","volume":"24","author":"Yao","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00041433-199506000-00002","article-title":"Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism","volume":"6","author":"Beisiegel","year":"1995","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0195","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0022-2275(20)33382-4","article-title":"N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a \"lipid pocket\" model for self-assembly of apob-containing lipoprotein particles","volume":"40","author":"Segrest","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-8674(92)90202-N","article-title":"Pause transfer: a topogenic sequence in apolipoprotein B mediates stopping and restarting of translocation","volume":"68","author":"Chuck","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0205","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0022-2275(20)37197-2","article-title":"Asymmetric distribution of pause transfer sequences in apolipoprotein B-100","volume":"38","author":"Kivlen","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0210","doi-asserted-by":"crossref","first-page":"27063","DOI":"10.1074\/jbc.M606809200","article-title":"Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet domains, not pause transfer sequences","volume":"281","author":"Yamaguchi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","article-title":"Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly","volume":"44","author":"Hussain","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0220","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0022-2275(20)30267-4","article-title":"Structure of apolipoprotein B-100 in low density lipoproteins","volume":"42","author":"Segrest","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0225","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/jmbi.1998.2298","article-title":"The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins","volume":"285","author":"Mann","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0230","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.ATV.14.10.1674","article-title":"apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE","volume":"14","author":"Segrest","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.ATV.9.1.96","article-title":"Structure of apolipoprotein B-100 of human low density lipoproteins","volume":"9","author":"Yang","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0240","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI1847","article-title":"Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100","volume":"101","author":"Boren","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0245","doi-asserted-by":"crossref","first-page":"19732","DOI":"10.1074\/jbc.M601688200","article-title":"Modular structure of solubilized human apolipoprotein B-100. Low resolution model revealed by small angle neutron scattering","volume":"281","author":"Johs","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/glycob\/cwi033","article-title":"Site-specific glycosylation analysis of human apolipoprotein B100 using LC\/ESI MS\/MS","volume":"15","author":"Harazono","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0255","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0260","doi-asserted-by":"crossref","first-page":"31872","DOI":"10.1074\/jbc.272.50.31872","article-title":"Identification of cysteine pairs within the amino-terminal 5% of apolipoprotein B essential for hepatic lipoprotein assembly and secretion","volume":"272","author":"Huang","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0265","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1074\/jbc.273.13.7244","article-title":"Functional analysis of disulfide linkages clustered within the amino terminus of human apolipoprotein B","volume":"273","author":"Tran","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0270","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1073\/pnas.92.5.1774","article-title":"Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes","volume":"92","author":"Farese","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0275","doi-asserted-by":"crossref","first-page":"21052","DOI":"10.1074\/jbc.M413877200","article-title":"Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor","volume":"280","author":"Benn","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0280","doi-asserted-by":"crossref","first-page":"21670","DOI":"10.1016\/S0021-9258(17)31858-6","article-title":"Human apolipoprotein B signal sequence variants confer a secretion-defective phenotype when expressed in yeast","volume":"269","author":"Sturley","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0285","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1093\/nar\/16.17.8361","article-title":"Truncated variants of apolipoprotein B cause hypobetalipoproteinaemia","volume":"16","author":"Collins","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0290","doi-asserted-by":"crossref","first-page":"11394","DOI":"10.1016\/S0021-9258(18)60477-6","article-title":"Hypobetalipoproteinemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-Alu recombination","volume":"264","author":"Huang","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0295","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1016\/S0021-9258(18)42116-3","article-title":"Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference","volume":"267","author":"Spring","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0300","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/S0021-9258(17)42021-7","article-title":"Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins","volume":"269","author":"McLeod","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0305","doi-asserted-by":"crossref","first-page":"337","DOI":"10.33549\/physiolres.930000.50.337","article-title":"Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis","volume":"50","author":"Vrablik","year":"2001","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0310","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-2275(20)42605-7","article-title":"Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia","volume":"31","author":"Innerarity","year":"1990","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0315","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1152\/physrev.00027.2011","article-title":"The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology","volume":"92","author":"Guerriero","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0320","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-nutr-071715-051030","article-title":"Endoplasmic reticulum-associated degradation and lipid homeostasis","volume":"36","author":"Stevenson","year":"2016","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0325","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4354","article-title":"In vivo aspects of protein folding and quality control","volume":"353","author":"Balchin","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0335","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0340","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbamcr.2011.09.002","article-title":"The Cdc48 machine in endoplasmic reticulum associated protein degradation","volume":"1823","author":"Wolf","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"22","key":"10.1016\/j.bbalip.2018.03.010_bb0345","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jmb.2017.05.027","article-title":"Proteasome structure and assembly","volume":"429","author":"Budenholzer","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0350","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1128\/MCB.21.13.4276-4291.2001","article-title":"In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulum quality control and sterol regulation","volume":"21","author":"Gardner","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0355","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1255638","article-title":"Quality control of inner nuclear membrane proteins by the Asi complex","volume":"346","author":"Foresti","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0360","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1073\/pnas.1213738110","article-title":"Spatial regulation of UBXD8 and p97\/VCP controls ATGL-mediated lipid droplet turnover","volume":"110","author":"Olzmann","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0365","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.95.25.14733","article-title":"Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence","volume":"95","author":"Mitchell","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0370","doi-asserted-by":"crossref","first-page":"13843","DOI":"10.1021\/bi9618777","article-title":"Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B","volume":"35","author":"Yeung","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0375","doi-asserted-by":"crossref","first-page":"20427","DOI":"10.1074\/jbc.272.33.20427","article-title":"The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70","volume":"272","author":"Fisher","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0380","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature23314","article-title":"Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3","volume":"548","author":"Schoebel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0385","doi-asserted-by":"crossref","first-page":"27225","DOI":"10.1074\/jbc.273.42.27225","article-title":"Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum","volume":"273","author":"Liao","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0390","doi-asserted-by":"crossref","first-page":"24891","DOI":"10.1074\/jbc.M100633200","article-title":"Apoprotein B degradation is promoted by the molecular chaperones hsp90 and hsp70","volume":"276","author":"Gusarova","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0395","doi-asserted-by":"crossref","first-page":"32665","DOI":"10.1074\/jbc.M705216200","article-title":"The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic reticulum-associated degradation (ERAD)","volume":"282","author":"Hrizo","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1091\/mbc.e11-08-0704","article-title":"Protein disulfide isomerases contribute differentially to the endoplasmic reticulum-associated degradation of apolipoprotein B and other substrates","volume":"23","author":"Grubb","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0405","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nrm2546","article-title":"One step at a time: endoplasmic reticulum-associated degradation","volume":"9","author":"Vembar","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0410","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.semcdb.2010.03.006","article-title":"Protein quality control in the ER: the recognition of misfolded proteins","volume":"21","author":"Maattanen","year":"2010","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0415","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbrc.2013.09.063","article-title":"Identification of the redox partners of ERdj5\/JPDI, a PDI family member, from an animal tissue","volume":"440","author":"Kadokura","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0420","doi-asserted-by":"crossref","first-page":"14536","DOI":"10.1073\/pnas.93.25.14536","article-title":"Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90","volume":"93","author":"Schneider","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2007.11.023","article-title":"Dissecting the ER-associated degradation of a misfolded polytopic membrane protein","volume":"132","author":"Nakatsukasa","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0430","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1091\/mbc.e17-01-0070","article-title":"Substrate binding by the yeast Hsp110 nucleotide exchange factor and molecular chaperone Sse1 is not obligate for its biological activities","volume":"28","author":"Garcia","year":"2017","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0435","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.201203061","article-title":"Aberrant substrate engagement of the ER translocon triggers degradation by the Hrd1 ubiquitin ligase","volume":"197","author":"Rubenstein","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0440","doi-asserted-by":"crossref","first-page":"23984","DOI":"10.1074\/jbc.M302683200","article-title":"Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells","volume":"278","author":"Liang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0445","doi-asserted-by":"crossref","first-page":"10105","DOI":"10.1021\/bi025749w","article-title":"The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100","volume":"41","author":"Cardozo","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0450","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1194\/jlr.M800108-JLR200","article-title":"The AAA-ATPase p97 facilitates degradation of apolipoprotein B by the ubiquitin-proteasome pathway","volume":"49","author":"Fisher","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0455","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1073\/pnas.0707460104","article-title":"Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control","volume":"105","author":"Pan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1194\/jlr.M043026","article-title":"Docosahexaenoic acid impairs the maturation of very low density lipoproteins in rat hepatic cells","volume":"55","author":"Maitin","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0465","doi-asserted-by":"crossref","first-page":"27855","DOI":"10.1074\/jbc.M008885200","article-title":"The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways","volume":"276","author":"Fisher","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0470","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1172\/JCI19197","article-title":"Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production","volume":"113","author":"Pan","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0475","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1091\/mbc.e05-07-0659","article-title":"Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B","volume":"17","author":"Ohsaki","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0480","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1172\/JCI63563","article-title":"Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism","volume":"122","author":"Strong","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0485","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1161\/CIRCRESAHA.117.311240","article-title":"Autophagy is required for sortilin-mediated degradation of apolipoprotein B100","volume":"122","author":"Amengual","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0490","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI116340","article-title":"N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes","volume":"91","author":"Wang","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0495","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1096\/fj.11-182725","article-title":"Role of superoxide radical anion in the mechanism of apoB100 degradation induced by DHA in hepatic cells","volume":"25","author":"Andreo","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0500","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ajcn\/78.6.1098","article-title":"Dietary linolenic acid is inversely associated with plasma triacylglycerol: the National Heart, Lung, and Blood Institute Family Heart Study","volume":"78","author":"Djousse","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0505","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.numecd.2016.07.012","article-title":"Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy","volume":"26","author":"Chan","year":"2016","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0510","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.1016\/S0021-9258(19)38966-5","article-title":"Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes","volume":"265","author":"Sparks","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0515","doi-asserted-by":"crossref","first-page":"E1003","DOI":"10.1152\/ajpendo.2000.279.5.E1003","article-title":"Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production","volume":"279","author":"Chirieac","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0520","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2007.11.013","article-title":"Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis","volume":"7","author":"Biddinger","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0525","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1074\/jbc.275.12.8416","volume":"275","author":"Taghibiglou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0530","doi-asserted-by":"crossref","first-page":"30693","DOI":"10.1074\/jbc.272.49.30693","article-title":"Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum","volume":"272","author":"Phung","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0535","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.0000249861.80471.96","article-title":"MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly","volume":"27","author":"Tsai","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0540","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/db06-0518","article-title":"Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins","volume":"56","author":"Qin","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0545","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.metabol.2003.09.011","article-title":"Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1\/PKBalpha","volume":"53","author":"Au","year":"2004","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0550","doi-asserted-by":"crossref","first-page":"G382","DOI":"10.1152\/ajpgi.00472.2005","article-title":"PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-\/- mice","volume":"291","author":"Chirieac","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057590","article-title":"Insulin-stimulated degradation of apolipoprotein B100: roles of class II phosphatidylinositol-3-kinase and autophagy","volume":"8","author":"Andreo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0560","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11886-017-0818-1","article-title":"Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes","volume":"19","author":"Khavandi","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0565","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/ATVBAHA.111.241356","article-title":"Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling","volume":"32","author":"Moon","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0570","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0575","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0580","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0585","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0590","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0595","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmet.2008.05.001","article-title":"Ezetimibe blocks internalization of the NPC1L1\/cholesterol complex","volume":"7","author":"Chang","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0600","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","article-title":"A neuromuscular approach to statin-related myotoxicity","volume":"35","author":"Baker","year":"2008","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0605","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0610","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0615","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6\u204e4 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0620","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mcp.2001.120251","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0625","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0635","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0640","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/0022-3859.90085","article-title":"Statin intolerance: now a solved problem","volume":"57","author":"Sikka","year":"2011","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0645","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8215.1","article-title":"Statin non-adherence: clinical consequences and proposed solutions","volume":"5","author":"Rosenson","year":"2016","journal-title":"F1000Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0650","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Cardiology patient page. Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0655","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0660","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0665","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0670","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cell.2017.05.032","article-title":"Beyond statins: new therapeutic frontiers for cardiovascular disease","volume":"169","author":"Narasimhan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0675","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1160\/TH16-10-0814","article-title":"Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future","volume":"117","author":"Weber","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0680","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11789-017-0085-0","article-title":"PCSK9 targets important for lipid metabolism","volume":"12","author":"Schulz","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0685","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.pharep.2016.03.016","article-title":"Current and future trends in the lipid lowering therapy","volume":"68","author":"Okopien","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0690","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0695","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0700","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0705","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005639","article-title":"Alirocumab treatment and achievement of non-high-density lipoprotein cholesterol and apolipoprotein B goals in patients with hypercholesterolemia: pooled results from 10 phase 3 ODYSSEY trials","volume":"6","author":"Bays","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0710","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0715","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0720","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(75)90182-8","article-title":"Regulation of the activity of the low density lipoprotein receptor in human fibroblasts","volume":"6","author":"Brown","year":"1975","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0725","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.174194","article-title":"Receptor-mediated control of cholesterol metabolism","volume":"191","author":"Brown","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0730","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0735","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CRD.0b013e31823424be","article-title":"Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia","volume":"20","author":"Ricotta","year":"2012","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0740","first-page":"119","article-title":"Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"Hosp. Formul. Manag."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0745","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0750","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0755","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0760","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0770","series-title":"FDA News Release","article-title":"FDA approves new orphan drug kynamro to treat inherited cholesterol disorder","author":"Liscinsky","year":"2013"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0775","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0780","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacl.2015.05.001","article-title":"Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide","volume":"9","author":"Roeters van Lennep","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0785","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0790","doi-asserted-by":"crossref","first-page":"588","DOI":"10.15698\/mic2016.12.546","article-title":"Autophagy: machinery and regulation","volume":"3","author":"Yin","year":"2016","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0795","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0800","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/ATVBAHA.114.303342","article-title":"Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae","volume":"34","author":"Emanuel","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0805","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15750","article-title":"Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis","volume":"8","author":"Sergin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0810","series-title":"Clinical Trials","article-title":"Far east memorial hospital, the influence of autophagy on fatty liver","volume":"vol. 2017","author":"Yu-Cheng Lin","year":"2017"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0815","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fnmol.2017.00263","article-title":"Autophagy dysregulation in ALS: when protein aggregates get out of hand","volume":"10","author":"Ramesh","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0820","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd.2017.22","article-title":"Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles","volume":"16","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0825","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fonc.2017.00128","article-title":"Autophagy in cancer therapy","volume":"7","author":"Fulda","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0830","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/10286020.2017.1304385","article-title":"Seeking new anti-cancer agents from autophagy-regulating natural products","volume":"19","author":"Hua","year":"2017","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0835","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-17-0151","article-title":"Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development","volume":"177","author":"Birzniece","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0840","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/jm020449y","article-title":"Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions","volume":"46","author":"Jordan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0845","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/jc.2010-0476","article-title":"Paracrine regulation of growth hormone secretion by estrogen in women","volume":"95","author":"Birzniece","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0850","doi-asserted-by":"crossref","first-page":"25220","DOI":"10.1074\/jbc.270.42.25220","article-title":"Apoprotein B100, an inefficiently translocated secretory protein, is bound to the cytosolic chaperone, heat shock protein 70","volume":"270","author":"Zhou","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0855","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/cb1000422","article-title":"Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40","volume":"5","author":"Wisen","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0860","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.bbalip.2018.03.010_bb0865","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbalip.2018.03.010_bb0870","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn3068","article-title":"Fighting neurodegeneration with rapamycin: mechanistic insights","volume":"12","author":"Bove","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"45","key":"10.1016\/j.bbalip.2018.03.010_bb0875","doi-asserted-by":"crossref","first-page":"E7049","DOI":"10.1073\/pnas.1604992113","article-title":"Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism","volume":"113","author":"Patel","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198118300519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198118300519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T19:55:54Z","timestamp":1720209354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198118300519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":175,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1388198118300519"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2018.03.010","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2018.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}